The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)

Pharmacogenetics and Genomics

Volumn 23, Issue 1, 2013, Pages 29-33

  Lewis, Lionel D ^a   Miller, Antonius A ^b   Owzar, Kouros ^c   Bies, Robert R ^d   Markova, Svetlana ^e   Jiang, Chen ^c   Kroetz, Deanna L ^e   Egorin, Merrill J ^f   McLeod, Howard L ^g   Ratain, Mark J ^h  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of North Carolina at Chapel Hill   (United States)

^e University of California   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

Author keywords

ABCC2 (pharmacogenetics); docetaxel; neutropenia; pharmacokinetics; SLCO1B3

Indexed keywords

DOCETAXEL; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1 B3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DRUG CLEARANCE; DRUG TRANSPORT; FEMALE; HEAD AND NECK CANCER; HUMAN; JAPANESE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEOPLASM; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

EID: 84871918938     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835b16d8     Document Type: Article

References (18)

1. Fulton B, Spencer CM. Docetaxel. A review of its pharmacodynamic andpharmacokinetic properties and therapeutic efficacy in the managementof metastatic breast cancer. Drugs 1996; 51:1075-1092.
2. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinicalpharmacology and therapeutic potential. Drugs 1998; 55:5-30. (Pubitemid 28035122)
3. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel:recent developments. Clin Pharmacokinet 2006; 45:235-252.
4. Eichelbaum M, Burk O. CYP3A genetics in drug metabolism. Nat Med2001; 7:285-287. (Pubitemid 32224337)
5. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification ofOATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. CancerBiol Ther 2005; 4:815-818.
6. Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH,Beijnen JH, van Tellingen O. Low systemic exposure of oral docetaxel in miceresulting from extensive first-pass metabolism is boosted by ritonavir. CancerRes 2002; 62:6158-6164. (Pubitemid 35244466)
7. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH.MRP2 (ABCC2) transports taxanes and confers paclitaxel resistanceand both processes are stimulated by probenecid. Int J Cancer 2005;116:824-829. (Pubitemid 41099717)
8. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y.Association of genetic polymorphisms in SLCO1B3 and ABCC2 withdocetaxel- induced leucopenia. Cancer Sci 2008; 99:967-972. (Pubitemid 351997599)
9. Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, et al.Cancer and Leukemia Group B. A comparison of the pharmacokineticsand pharmacodynamics of docetaxel between African-American andCaucasian cancer patients: CALGB 9871. Clin Cancer Res 2007;13:3302-3311. (Pubitemid 46944916)
10. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB.A population pharmacokinetic model for docetaxel (Taxotere):model building and validation. J Pharmacokinet Biopharm 1996;24:153-172. (Pubitemid 26300483)
11. Hirouchi M, Suzuki H, Itoda M, Ozawa S, Sawada J, Ieiri I, et al.Characterization of the cellular localization, expression level, and functionof SNP variants of MRP2/ABCC2. Pharm Res 2004; 21:742-748. (Pubitemid 39011294)
12. Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF,Mokrab Y, et al. Identification of novel functional organic anion-transportingpolypeptide 1B3 polymorphisms and assessment of substrate specificity.Pharmacogenet Genomics 2011; 21:103-114.
13. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, et al.Pharmacogenetic pathway analysis of docetaxel elimination. Clin PharmacolTher 2009; 85:155-163.
14. Chew SC, Singh O, Chen X, Ramasamy RD, Kulkarni T, Lee EJ, et al. Theeffects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3single nucleotide polymorphisms on the pharmacokinetics andpharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.Cancer Chemother Pharmacol 2011; 67:1471-1478.
15. Bosch TM, Huitema AD, Doodeman VD, Jansen R,Witteveen E, Smit WM,et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation topopulation pharmacokinetics of docetaxel. Clin Cancer Res 2006;12:5786-5793. (Pubitemid 44629610)
16. ZamboniWC, Combest AJ, Deloia JA, Edwards RP, Bridges AS, Zamboni BA,et al. Pharmacologic and phenotypic study of docetaxel in patients with ovarianor primary peritoneal cancer. Cancer Chemother Pharmacol 2011;68:1255-1262.
17. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE,et al. Influence of polymorphic OATP1B-type carriers on the disposition ofdocetaxel. Clin Cancer Res 2012; 18:4433-4440.
18. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, et al.Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GSTpolymorphisms. Clin Pharmacol Ther 2006; 79:570-580. (Pubitemid 43833447)